Seven members of Ace meet at AD/PD 2022
Ace has a prominent presence at the AD/PD 2022 congress, the international conference on Alzheimer's, Parkinson's and other neurological diseases, which takes place between 15th and 20th March in Barcelona.
Approaching Alzheimer's disease in an innovative way
Dr. Mercè Boada, co-founder and chief medical officer of Ace Alzheimer Center Barcelona, chairs the Grifols symposium “Novel approaches in AD: Cutting Edge Science, Diagnostic and Therapeutic Strategies”.
Together with great international researchers such as Dr. Charlotte Teunissen, Dr. Tony Wyss-Coray and Dr. Timo Grimmer, will talk about new approaches for the diagnosis of Alzheimer's, with special emphasis on new plasma biomarkers, much more accessible and less invasive.
For her part, Montse Costa, director of plasma protein research at Grifols, will focus on new treatments for Alzheimer's through plasmapheresis.
The symposium will be held on Friday, March 18, at 9:10 a.m. In this link you will find more information about the session.
The future of Alzheimer's disease
"Where does our hope come from in Alzheimer’s disease?” This is the interesting session promoted by Roche, chaired by Dr. Jean Gorges and in which Dr. Boada will participate along with other international researchers such as Dr. Abdulrazak Abyad, Dr. Ishtar Govia and Dr. Jonathan L.Liss.
The symposium will be held on Friday, March 18, at 12:15 p.m. In this link you will find more information about the session.
Multiple Ace Studies Featured at AD/PD 2022
In addition to the active participation of the medical director, Ace is very present in this hybrid edition of the congress, presenting different studies resulting from the genomic and clinical research that has been carried out in recent years.
Dr. Amanda Cano will present on Saturday, March 19, one of the latest publications on the BIOFACE project, a study that analyzes the diagnostic potential of new biomarkers in people under 65 with mild cognitive impairment. This session is chaired by Dr. Mercè Boada and you can find more information about it at this link.
Itziar de Rojas, predoctoral researcher at Ace, participates on Sunday, March 20, in the symposium on the impact of Covid-19 on neurodegenerative diseases. De Rojas will present a study carried out within the framework of the GR@ACE project in which susceptibility factors associated with Covid-19 are sought in this group of people. You can find more information about the session at this link.
For her part, Dr. Marta Marquié, head of clinical research at Ace, presents one of the latest studies from the NORFACE project in which the relationship between retinal thickness and cognitive impairment is analyzed.
In addition to presenting these latest studies, Dr. Marquié and Ainhoa García-Sánchez, bioinformatician at Ace, will present two studies on our FACEHBI cohort, made up of people with subjective memory complaints, and the one in which we tried to verify whether these complaints are a reliable marker to develop dementia.
See the full program of the AD/PD conference.